Investor Presentaiton

R&D investor presentation Cardiovascular disease is an area with a large unmet need and strong strategic fit with our core therapy areas ~510 million people live with cardiovascular disease¹, which is estimated to increase to 530 million in 2030 ~18 million people die² each year from cardiovascular disease, an estimated 31% of all deaths globally. Of these CVD deaths, 85% are due to heart attacks and strokes Heart failure, non-fatal stroke and myocardial infarctions have large influence on quality of life 23 23 OVERLAPPING PATIENT SEGMENTS IN T2D, OBESITY AND CVD1 ILLUSTRATIVE CVD T2D Obesity Novo Nordisk's focus within CVD is on atherosclerotic cardiovascular disease and heart failure driven by the large unmet need and link to Novo Nordisk core therapeutic areas type 2 diabetes and obesity • 70% of diabetes patients die from atherosclerotic CVD • 40% of patients who are hospitalised for heart failure have diabetes 1 GBI Research Proprietary Epidemiology Database, 2018 2 www.who.int/health-topics/cardiovascular-diseases/#tab-tab_1 CVD: Cardiovascular disease; T2D: Type 2 diabetes novo nordisk

View entire presentation